A gyulladásos bélbetegségek farmakogenetikája

Translated title of the contribution: Pharmacogenetics of inflammatory bowel disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There are interindividual variations with regard to efficacy and toxicity of many commonly employed drugs. Major causes of interindividual differences of drug effects include genetic variations of drug-metabolizing enzymes, transporters and targets. Pharmacogenetics studies the genetic background of the interindividual variations of drug response. By means of preliminary genetic screening personalized treatment can be achieved, drugs with low efficacy and many side-effects can be avoided. The pharmacogenetically best studied medications of inflammatory bowel disease are azathioprine/6-mercaptopurine. It is obvious that there is a genetic background of the efficacy and toxicity of corticosteroids, 5-ASA drugs, infliximab and other immunosuppressors as well, but further studies now require to confirm the functional significance of it. Therefore, at present, the application and clinical usefulness of pharmacogenetics in the management of inflammatory bowel disease is limited. The aims of future investigations are understanding of the mechanism of drug action, identification of new drug targets and acquainting with genetic factors that determine drug response.

Original languageHungarian
Pages (from-to)1143-1150
Number of pages8
JournalOrvosi Hetilap
Volume146
Issue number21
Publication statusPublished - 2005

Fingerprint

Pharmacogenetics
Inflammatory Bowel Diseases
Pharmaceutical Preparations
6-Mercaptopurine
Azathioprine
Genetic Testing
Adrenal Cortex Hormones
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A gyulladásos bélbetegségek farmakogenetikája. / Hagymási, K.; Tulassay, Z.

In: Orvosi Hetilap, Vol. 146, No. 21, 2005, p. 1143-1150.

Research output: Contribution to journalArticle

@article{a47e61df91324362bbbc65d474c7b7af,
title = "A gyullad{\'a}sos b{\'e}lbetegs{\'e}gek farmakogenetik{\'a}ja",
abstract = "There are interindividual variations with regard to efficacy and toxicity of many commonly employed drugs. Major causes of interindividual differences of drug effects include genetic variations of drug-metabolizing enzymes, transporters and targets. Pharmacogenetics studies the genetic background of the interindividual variations of drug response. By means of preliminary genetic screening personalized treatment can be achieved, drugs with low efficacy and many side-effects can be avoided. The pharmacogenetically best studied medications of inflammatory bowel disease are azathioprine/6-mercaptopurine. It is obvious that there is a genetic background of the efficacy and toxicity of corticosteroids, 5-ASA drugs, infliximab and other immunosuppressors as well, but further studies now require to confirm the functional significance of it. Therefore, at present, the application and clinical usefulness of pharmacogenetics in the management of inflammatory bowel disease is limited. The aims of future investigations are understanding of the mechanism of drug action, identification of new drug targets and acquainting with genetic factors that determine drug response.",
keywords = "5-ASA, Azathioprine/mercaptopurine, Corticosteroids, Drug metabolism, Inflammatory bowel disease, Infliximab, Pharmacogenetics",
author = "K. Hagym{\'a}si and Z. Tulassay",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1143--1150",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "21",

}

TY - JOUR

T1 - A gyulladásos bélbetegségek farmakogenetikája

AU - Hagymási, K.

AU - Tulassay, Z.

PY - 2005

Y1 - 2005

N2 - There are interindividual variations with regard to efficacy and toxicity of many commonly employed drugs. Major causes of interindividual differences of drug effects include genetic variations of drug-metabolizing enzymes, transporters and targets. Pharmacogenetics studies the genetic background of the interindividual variations of drug response. By means of preliminary genetic screening personalized treatment can be achieved, drugs with low efficacy and many side-effects can be avoided. The pharmacogenetically best studied medications of inflammatory bowel disease are azathioprine/6-mercaptopurine. It is obvious that there is a genetic background of the efficacy and toxicity of corticosteroids, 5-ASA drugs, infliximab and other immunosuppressors as well, but further studies now require to confirm the functional significance of it. Therefore, at present, the application and clinical usefulness of pharmacogenetics in the management of inflammatory bowel disease is limited. The aims of future investigations are understanding of the mechanism of drug action, identification of new drug targets and acquainting with genetic factors that determine drug response.

AB - There are interindividual variations with regard to efficacy and toxicity of many commonly employed drugs. Major causes of interindividual differences of drug effects include genetic variations of drug-metabolizing enzymes, transporters and targets. Pharmacogenetics studies the genetic background of the interindividual variations of drug response. By means of preliminary genetic screening personalized treatment can be achieved, drugs with low efficacy and many side-effects can be avoided. The pharmacogenetically best studied medications of inflammatory bowel disease are azathioprine/6-mercaptopurine. It is obvious that there is a genetic background of the efficacy and toxicity of corticosteroids, 5-ASA drugs, infliximab and other immunosuppressors as well, but further studies now require to confirm the functional significance of it. Therefore, at present, the application and clinical usefulness of pharmacogenetics in the management of inflammatory bowel disease is limited. The aims of future investigations are understanding of the mechanism of drug action, identification of new drug targets and acquainting with genetic factors that determine drug response.

KW - 5-ASA

KW - Azathioprine/mercaptopurine

KW - Corticosteroids

KW - Drug metabolism

KW - Inflammatory bowel disease

KW - Infliximab

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=22144494656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144494656&partnerID=8YFLogxK

M3 - Article

C2 - 15991678

AN - SCOPUS:22144494656

VL - 146

SP - 1143

EP - 1150

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 21

ER -